Journal Article

DKFZ-2019-02342

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png EASIX and mortality after allogeneic stem cell transplantation.

Luft, T. ; Benner, A.DKFZ* ; Terzer, T.DKFZ* ; Jodele, S. ; Dandoy, C. E. ; Storb, R. ; Kordelas, L. ; Beelen, D. ; Gooley, T. ; Sandmaier, B. M. ; Sorror, M. ; Zeisbrich, M. ; Radujkovic, A. ; Dreger, P. ; Penack, O.

2020
Nature Publishing Group55086 London

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/s41409-019-0703-1

Abstract: Allogeneic stem cell transplantation (alloSCT) is an effective immunotherapy in patients with hematological malignancies. Endothelial dysfunction was linked to major complications after alloSCT. We asked the question if the 'Endothelial Activation and Stress Index' (EASIX; [(creatinine × LDH) ÷ thrombocytes]) can predict mortality after alloSCT. We performed a retrospective cohort analysis in five alloSCT centers in the USA and Germany. EASIX was assessed prior to conditioning (EASIX-pre) and correlated with mortality in 755 patients of a training cohort in multivariable models. The predictive model established in the training cohort was validated in 1267 adult allo-recipients. Increasing EASIX-pre predicted lower overall survival (OS) after alloSCT, and successful model validation was achieved for the validation cohort. We found that EASIX-pre predicts OS irrespective of established scores. Moreover, EASIX-pre was also a significant prognostic factor for transplant-associated microangiopathy. Finally, EASIX-pre correlated with biomarkers of endothelial homeostasis such as CXCL8, interleukin-18, and insulin-like-growth-factor-1 serum levels. This study establishes EASIX-pre based on a standard laboratory biomarker panel as a predictor of individual risk of mortality after alloSCT independently from established clinical criteria.

Note: 2020 Mar;55(3):553-561

---

Contributing Institute(s):

1. C060 Biostatistik (C060)

Research Program(s):

1. 313 - Cancer risk factors and prevention (POF3-313) (POF3-313)

Appears in the scientific report 2020

---

Database coverage:
; BIOSIS Previews ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection

---